The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. People who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will be will be randomly assigned to either have the ERCP with sphincterotomy procedure, or to have a "sham" procedure, meaning that you will be treated as if you are having the ERCP with sphincterotomy procedure but the procedure will not really be performed. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until the study ends.
The main purpose of this study is to see if taking dupilumab is effective in treating Eosinophilic Esophogitis (EoE). The study will determine if dupilumab is an effective treatment compared with placebo in adult and adolescent patients. Dupilumab is administered through a subcutaneous injection (shot). Dupilumab is is an investigational drug, which means that it is not yet approved to treat EoE. Participation in the study will last up to 48 weeks.
Adult patients (18 years and older) who receive treatment for HIV in the MUSC Infectious Diseases Clinic will be offered participation in this study. This study will asses whether receipt of injectable HIV therapy at home with a Home Health provider is as safe and effective as receiving treatment in clinic. Participants receiving injectable HIV therapy prescribed by their primary HIV physician will choose to receive the monthly injection at home or in a clinic setting and will have the option to change where they receive treatment at any time. Questionnaires will be completed at the beginning and end of treatment along with a monthly satisfaction survey. Participation in the study is expected to last approximately 1 year.